13,520 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Syon Capital LLC

by · The Markets Daily

Syon Capital LLC purchased a new position in Exact Sciences Co. (NASDAQ:EXAS – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 13,520 shares of the medical research company’s stock, valued at approximately $760,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Thompson Investment Management Inc. boosted its position in Exact Sciences by 17.8% in the fourth quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company’s stock valued at $13,585,000 after buying an additional 36,505 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Exact Sciences by 35.3% in the 4th quarter. Harbor Capital Advisors Inc. now owns 95,827 shares of the medical research company’s stock valued at $5,385,000 after acquiring an additional 24,992 shares during the last quarter. Jones Financial Companies Lllp increased its stake in shares of Exact Sciences by 32.2% in the fourth quarter. Jones Financial Companies Lllp now owns 9,508 shares of the medical research company’s stock worth $534,000 after acquiring an additional 2,315 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of Exact Sciences in the fourth quarter worth $478,000. Finally, Sanctuary Advisors LLC raised its holdings in shares of Exact Sciences by 2.0% during the fourth quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company’s stock worth $763,000 after purchasing an additional 269 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Price Performance

Shares of NASDAQ EXAS opened at $44.09 on Thursday. The firm has a 50-day simple moving average of $45.50 and a 200-day simple moving average of $54.54. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The stock has a market capitalization of $8.19 billion, a price-to-earnings ratio of -7.92 and a beta of 1.14. Exact Sciences Co. has a 52 week low of $39.97 and a 52 week high of $72.83.

Exact Sciences (NASDAQ:EXAS – Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. On average, equities analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Bank of America cut their price target on Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Scotiabank boosted their target price on shares of Exact Sciences from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research note on Monday, February 24th. Piper Sandler dropped their price target on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Royal Bank of Canada initiated coverage on shares of Exact Sciences in a research report on Thursday, March 13th. They issued a “sector perform” rating and a $52.00 price objective for the company. Finally, Mizuho began coverage on Exact Sciences in a research report on Thursday, April 10th. They set an “outperform” rating and a $60.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $69.25.

View Our Latest Stock Analysis on EXAS

About Exact Sciences

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

See Also